Forensic toxicology
July 1, 2023
Rie Tanaka, Maiko Kawamura, Sakumi Mizutani et al.
18 citations
Three new analogs of LSD have been identified in paper sheet products sold as designer drugs in Japan. Using mass spectrometry and nuclear magnetic resonance spectroscopy, the compounds were determined to be 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD, and LSZ. Compared to LSD, 1cP-AL-LAD is modified at two positions (N1 and N6), and 1cP-MIPLA at N1 and N18. The metabolic pathways and biological activities of 1cP-AL-LAD and 1cP-MIPLA are not yet reported. This is the first report of LSD analogs with multiple structural modifications detected in sheet products in Japan, raising concerns about future distribution and highlighting the need for continued monitoring.
Drug testing and analysis
May 1, 2024
Rie Tanaka, Maiko Kawamura, Sakumi Mizutani et al.
11 citations
A paper-sheet product sold as containing the LSD analog 1D-LSD actually contained a different, previously unreported compound: 1-thiophenoyl LSD (1T-LSD). Using mass spectrometry and nuclear magnetic resonance spectroscopy, the compound was identified as having a thiophene-2-carbonyl group instead of the claimed 1,2-dimethylcyclobutane-carbonyl group. Each unit of the sheet contained 87–100 μg of 1T-LSD free base. The compound slowly converted to LSD in methanol-d4 during analysis. Its UV spectrum differed from other LSD analogs, and its fluorescence was much lower. The authors recommend continued monitoring of sheet products for new LSD analogs.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
January 1, 2022
Rie Tanaka, Maiko Kawamura, Sakumi Mizutani et al.
3 citations
Three new derivatives of the dissociative drug methoxetamine (MXE) were identified in illegal products in Japan: methoxpropamine (MXPr), methoxisopropamine (MXiPr), and deoxymethoxetamine (DMXE). MXE itself, an analog of the anesthetic ketamine, is already controlled as a narcotic in Japan, and its overdoses have caused health problems. All arylcyclohexylamines, including these new substances, act as antagonists of the NMDA receptor. The findings highlight the ongoing emergence of novel psychoactive substances designed to evade legal controls.